Key facts
- Evido’s last known valuation is $13.8M (Jan 2025).
- It has raised $1.8M; the latest was Early Stage VC ($1.4M) in Jan 2025.
- Notable investors include European Commission, InnoFounder, Nordic Mentor Network For Entrepreneurship, BETA.HEALTH, People Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Evido
- ·The full record, as it builds
Funding rounds
No funding rounds for Evido are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Evido
Developer of a disease detection platform intended to track fatty liver disease. The company's technology provides clinicians with actionable data insights and specific clinical recommendations that fit their workflow, enabling clinicians to empower patients' data and bridge a crucial gap in current healthcare practices.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2021
- Employees
- 18
- Website
- evido.health/
- Ownership
- Privately Held (backing)
Evido doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Evido shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Evido in its N-PORT filings yet. We sweep new filings monthly.